Home/Sanofi/Christel Heydemann

CH

Christel Heydemann

Proposed Independent Director

Therapeutic Areas

Immunology Rare Diseases Multiple Sclerosis Diabetes Vaccines

Sanofi Pipeline

Drug	Indication	Phase
Venglustat	Type 3 Gaucher disease	Phase 3
Rilzabrutinib	IgG4-related disease	Clinical
Dupixent	Atopic dermatitis	Commercial
Toujeo	Diabetes	Commercial
Lantus	Diabetes	Commercial